Norwegian version of this page

Clinical Retina Research

The main aim of our research is clinical implementation and evaluation of new treatment, and diagnostic modalities for vitreoretinal disorders.

The research group consists of doctors and other health professionals at the Eye Departments of UiO and OUH. We study and treat patients with retinal diseases.

Projects

  • Artificial intelligence for diagnosing retinal diseases
  • The Z-AMD study: A randomized controlled pilot study of zoledronic acid as adjuvant treatment for nAMD

  • The TenCRAOS study: a randomized controlled international multicenter study of trombolysis for central retinal artery occlusion

  • StrokeVIS: a study of prevalence and screening for visual problems in stroke

  • An evidence-based approach to the European visual requirements for driving

  • Individually adjusted screening program for diabetic retinopathy by using different non-invasive measurements and symptoms

  • Development of an adjustable glaucoma stent

  • Intravitreal injections and the development of prefilled syringes for anti-VEGF treatment

  • Endophthalmitis: epidemiology and treatment

  • Project RP11: A collaborating study between Dept. of Microbiology and Dept. of Ophthalmology, Oslo University Hospital. Includes the Natural history study of retinitis pigmentosa type 11 (ReSa study) investigating both clinical and pathophysiological features and progression of retinitis pigmentosa type 11 with the aim of treating the disorder.

  • MIP genetisk analyse av pasienter med retinitis pigmentosa og Lebers kongenitale amaurose: Goal of uncovering the genetic diagnosis of all RP and LCA patients in Norway

  • Clinical and genetic characterization of BEST1-retinal dystrophy in South-East Norway

  • PERCEIVE study: International multicenter study for post approval evaluation of the effect and safety of voretigene neparvovec

  • CELESTE study: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Early to Moderate Vision Loss (phase 2/3)

  • SIRIUS study: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision Loss (phase 2/3)

  • Uveitis registry at OUH

  • Registry of inherited retinal diseases in Norway

  • Automatic grading of retinal images (Kunstig intelligens)

  • Risk stratification in diabetic retinopathy

  • Randomized pilot trial comparing efficacy of adalimumab and tocilizumab in non-infectious uveitis (the @-uveitis study)

  • The application of ultra-widefield fundus autofluorescence in the diagnosis and monitoring treatment effect of various retinal diseases and choroidal melanoma

  • Characterizing the genotype, phenotype, health issues, physical functioning and quality of life in adults with Bardet Biedl syndrome

Coopeation

This broad range of methods requires close collaboration with research groups in Norway and abroad.

National

  • Anne Hege Aamodt, Dept. of Neurology, OUH
  • Jan Terje Andersen, Dept. of Immunology, OUH
  • Rigmor Baraas, Dept. of Optometry and Visual Science, Campus Kongsberg, University of South-Eastern Norway

  • Magnar Bjørås, Dept. of Microbiology, OUH, Department of Clinical and Molecular Medicine, NTNU

  • Erik Fink Eriksen, Dept. of Endocrinology, Morbid Obesity and Preventive Medicine, OUH

  • Maja Gran Erke, The Directorate of eHealth

  • Johan Arild Evang, Section of Specialized Endocrinology, OUH
  • Stian Foss, Dept. of Pharmacology, UiO
  • Stuart Gilson, University of South-Eastern Norway
  • Lene Aarvelta Hagen, University of South-Eastern Norway
  • Nils Olav Hermansen, Dept. of Microbiology, OUH
  • Mona Holberg-Petersen, Dept. of Microbiology, OUH
  • Inven2
  • Elise Dees Krekling, University of South-Eastern Norway
  • Sjur Lindbæk, Statped
  • Charlotta von der Lippe, Dept. of Rare Disorders and Disabilities, OUH
  • Jeanette Ullman Miller, Dept. of Rare Disorders and Disabilities, OUH
  • Hilde Nordgarden, TAKO centre, Lovisenberg Diaconal Hospital
  • Hilde Røgeberg Pedersen, University of South-Eastern Norway
  • Trine Prescott, Telemark Hospital Trust
  • Cecilie Rustad, Dept. of Medical Genetics, OUH
  • Stephen Ryan, Dept. of Neurology, OUH
  • Solrun Sigurdardottir, Dept. of Rare Disorders and Disabilities, OUH
  • Erlend Sæther master student, University Hospital of North Norway
  • Marie Elisabeth Vad, Dept. of Microbiology, OUH
  • Susanne Weedon-Fekjær, Dept. of Rare Disorders and Disabilities, OUH
  • Pamela Åsten, TAKO centre, Lovisenberg Diaconal Hospital

International

  • Tomas Bro, Lund University, Sweden
  • Frans Cremers, Radbound University, Nijmegen, Netherlands
  • Mojca Globocnik-Petrovic, Ljubljana, Slovenia
  • Novartis, Switzerland
  • ProQR Therapeutics, Netherlands
  • Fiona Rowe, University of Liverpool, United Kingdom
  • Greg Russel, EyeNuk inc.,Cheshire, United Kingdom
  • SJJ Solution, Netherlands
  • Einar Stefansson, EyeRisk , Reykjavik, Iceland
  • Demetrios G. Vavvas, Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA
Published Feb. 1, 2016 3:25 PM - Last modified Nov. 12, 2021 4:58 PM

Contact

Group leader

Participants

Detailed list of participants